Literature DB >> 20130070

Use of organic nitrates and the risk of hip fracture: a population-based case-control study.

Sander Pouwels1, Arief Lalmohamed, Tjeerd van Staa, Cyrus Cooper, Patrick Souverein, Hubertus G Leufkens, Lars Rejnmark, Anthonius de Boer, Peter Vestergaard, Frank de Vries.   

Abstract

CONTEXT: Use of organic nitrates has been associated with increased bone mineral density. Moreover, a large Danish case-control study reported a decreased fracture risk. However, the association with duration of nitrate use, dose frequency, and impact of discontinuation has not been extensively studied.
OBJECTIVE: Our objective was to evaluate the association between organic nitrates and hip fracture risk.
METHODS: A case-control study was conducted using the Dutch PHARMO Record Linkage System (1991-2002, n = 6,763 hip fracture cases and 26,341 controls). Cases had their first admission for hip fracture, whereas controls had not sustained any fracture after enrollment. Current users of organic nitrates were patients who had received a prescription within 90 d before the index date. The analyses were adjusted for disease and drug history.
RESULTS: Current use of nitrates was not associated with a decreased risk of hip fracture [adjusted odds ratio (OR) = 0.93; 95% confidence interval (CI) = 0.83-1.04]. Those who used as-needed medication only had a lower risk of hip fracture (adjusted OR = 0.83; 95% CI = 0.63-1.08) compared with users of maintenance medication only (adjusted OR = 1.17; 95% CI = 0.97-1.40). No association was found between duration of nitrate use and fracture risk.
CONCLUSIONS: Our overall analyses showed that risk of a hip fracture was significantly lower among users of as-needed organic nitrates, when compared with users of maintenance medication. Our analyses of hip fracture risks with duration of use did not further support a beneficial effect of organic nitrates on hip fracture, although residual confounding may have masked beneficial effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130070      PMCID: PMC2853998          DOI: 10.1210/jc.2009-2342

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

1.  Nitrate use and changes in bone mineral density: the Canadian Multicentre Osteoporosis Study.

Authors:  S A Jamal; D Goltzman; D A Hanley; A Papaioannou; J C Prior; R G Josse
Journal:  Osteoporos Int       Date:  2008-09-18       Impact factor: 4.507

2.  Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis.

Authors:  Ashraf F Nabhan; Noha H Rabie
Journal:  Int J Gynaecol Obstet       Date:  2008-09-21       Impact factor: 3.561

3.  Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis.

Authors:  K E Armour; R J Van'T Hof; P S Grabowski; D M Reid; S H Ralston
Journal:  J Bone Miner Res       Date:  1999-12       Impact factor: 6.741

4.  Decreased fracture risk in users of organic nitrates: a nationwide case-control study.

Authors:  Lars Rejnmark; Peter Vestergaard; Leif Mosekilde
Journal:  J Bone Miner Res       Date:  2006-11       Impact factor: 6.741

5.  Roles of COX-2 and iNOS in the bony repair of the injured growth plate cartilage.

Authors:  G Arasapam; M Scherer; J C Cool; B K Foster; C J Xian
Journal:  J Cell Biochem       Date:  2006-10-01       Impact factor: 4.429

6.  Nitric oxide stimulates proliferation and differentiation of fetal calvarial osteoblasts and dural cells.

Authors:  Ines C Lin; James M Smartt; Hyun-Duck Nah; Harry Ischiropoulos; Richard E Kirschner
Journal:  Plast Reconstr Surg       Date:  2008-05       Impact factor: 4.730

7.  Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures.

Authors:  S A Jamal; W S Browner; D C Bauer; S R Cummings
Journal:  J Bone Miner Res       Date:  1998-11       Impact factor: 6.741

8.  Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss.

Authors:  Sunil J Wimalawansa; Julia P Grimes; Alan C Wilson; Donald R Hoover
Journal:  J Clin Endocrinol Metab       Date:  2009-06-23       Impact factor: 5.958

9.  Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study.

Authors:  F de Vries; S Pouwels; J W J Lammers; H G M Leufkens; M Bracke; C Cooper; T P van Staa
Journal:  J Intern Med       Date:  2007-02       Impact factor: 8.989

10.  Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.

Authors:  F de Vries; P C Souverein; C Cooper; H G M Leufkens; T P van Staa
Journal:  Calcif Tissue Int       Date:  2007-02-02       Impact factor: 4.333

View more
  18 in total

1.  A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.

Authors:  Hema Kalyanaraman; Ghania Ramdani; Jisha Joshua; Nadine Schall; Gerry R Boss; Esther Cory; Robert L Sah; Darren E Casteel; Renate B Pilz
Journal:  J Bone Miner Res       Date:  2016-09-07       Impact factor: 6.741

2.  Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation.

Authors:  Zixue Jin; Jordan Kho; Brian Dawson; Ming-Ming Jiang; Yuqing Chen; Saima Ali; Lindsay C Burrage; Monica Grover; Donna J Palmer; Dustin L Turner; Philip Ng; Sandesh Cs Nagamani; Brendan Lee
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 3.  Antihypertensive medications, bone mineral density, and fractures: a review of old cardiac drugs that provides new insights into osteoporosis.

Authors:  Mahua Ghosh; Sumit R Majumdar
Journal:  Endocrine       Date:  2014-02-07       Impact factor: 3.633

Review 4.  Nitric oxide donors for the treatment of osteoporosis.

Authors:  Sophie A Jamal; Celeste J Hamilton
Journal:  Curr Osteoporos Rep       Date:  2012-03       Impact factor: 5.096

5.  Soluble guanylate cyclase as a novel treatment target for osteoporosis.

Authors:  Jisha Joshua; Gerburg K Schwaerzer; Hema Kalyanaraman; Esther Cory; Robert L Sah; Mofei Li; Florin Vaida; Gerry R Boss; Renate B Pilz
Journal:  Endocrinology       Date:  2014-09-04       Impact factor: 4.736

6.  Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study.

Authors:  B Abrahamsen; K H Rubin; P A Eiken; R Eastell
Journal:  Osteoporos Int       Date:  2012-10-16       Impact factor: 4.507

7.  Organic nitrates for osteoporosis: an update.

Authors:  Celeste J Hamilton; Lauren S Reid; Sophie A Jamal
Journal:  Bonekey Rep       Date:  2013-02-06

Review 8.  Heart failure as a risk factor for osteoporosis and fractures.

Authors:  Aloice O Aluoch; Ryan Jessee; Hani Habal; Melinda Garcia-Rosell; Rehan Shah; Guy Reed; Laura Carbone
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

9.  Nitrate Medications, Fractures, and Change in Bone Mineral Density in Postmenopausal Women: Results from the Women's Health Initiative.

Authors:  Negar Golchin; Chancellor Hohensee; Andrea LaCroix; Shelly L Gray
Journal:  J Bone Miner Res       Date:  2016-07-11       Impact factor: 6.741

10.  Medication use before and after hip fracture: a population-based cohort and case-control study.

Authors:  Maurizio Rossini; Ombretta Viapiana; Silvano Adami; Luca Idolazzi; Stefano Buda; Chiara Veronesi; Luca Degli Esposti; Davide Gatti
Journal:  Drugs Aging       Date:  2014-07       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.